Versa Networks is Industry’s First SASE Provider to Earn Compliance with ‘Make in India’ Initiative
‘Make in India’ Initiative Compliance Offers Competitive Advantage in the Rapidly Growing India Market, Particularly…
Month: January 2023
Evolv Technology® Works with James Island Charter High School to Help Make Safer Classrooms and Athletic Facilities
James Island joins more than 200 schools across the U.S. using Evolv WALTHAM, Mass.–(BUSINESS WIRE)–Evolv…
Wireless Customers More Attached to Phones as Satisfaction Increases, J.D. Power Finds
Verizon Ranks Highest in Five Regions, Tying with T-Mobile in Northeast Region; AT&T Ranks Highest…
Twist Bioscience to Report Fiscal 2023 First Quarter Financial Results on Friday, February 3, 2023
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed…
TSN and Genius Sports Partner to Deliver Inaugural Augmented NFL Playoff and Super Bowl Feeds on TSN+
Genius Sports to supply TSN’s new TSN+ direct-to-consumer streaming product with real-time data-driven broadcast overlays…
Crossword Cybersecurity partners with BCS, The Chartered Institute for IT
Partnership to support BCS members with cybersecurity and cyber supply chain resilience 19th January 2023…
2023 and Beyond: Why Web3 is the Future of the Internet
By Tomi Brooks, Executive Officer, Head of Business Development — double jump.tokyo A huge part…
InvestmentPitch Media Video Discusses FSD Pharma’s Submission of its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS, a Candidate for Treatment of MS
VANCOUVER, British Columbia, Jan. 19, 2023 (GLOBE NEWSWIRE) — FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A),…
Aneka Jaringan Posts Revenue of RM53 Million in 1Q FY2023
KUALA LUMPUR, Jan 19, 2023 – (ACN Newswire) – Aneka Jaringan Holdings Berhad (Bursa: ANEKA,…
HKTDC’s four major focus areas create opportunities via Hong Kong
HONG KONG, Jan 19, 2023 – (ACN Newswire) – As Hong Kong reopens its doors…
CITIC Telecom CPC Has a Rosy Start in 2023 with Multiple Distinguished Awards and Certifications
HONG KONG, Jan 19, 2023 – (ACN Newswire) – CITIC Telecom International CPC Limited (CITIC…
WNS Announces Fiscal 2023 Third Quarter Earnings, Revises Full Year Guidance
NEW YORK & MUMBAI, India–(BUSINESS WIRE)–$WNS #BPM–WNS (Holdings) Limited (WNS) (NYSE: WNS), a leading provider…
NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager
New liver tissue dataset highlights high sensitivity and specificity of CosMx system, and the biological…
Nova Credit Receives Authorisation to Become UK’s First Cross-Border Credit Reference Provider
Nova Credit receives permissions from the Financial Conduct Authority necessary to operate in the UK…
Digi International Launches Digi ConnectCore® Services, Offering Software Foundation that Enables Manageability and Security of Digi ConnectCore Family of SOMs
Digi ConnectCore® Cloud Services and Digi ConnectCore® Security Services enable OEMs to create highly manageable…
Champions League final boots European eCommerce sales to lowest point in 2022
eCommerce sales in Europe drop on Saturday 28th May, the same day as the Champions…
BICS to power its suite of advanced Software as a Service (SaaS) solutions through Infovista
Enables software economies of scale for BICS’ analytics customers with hassle-free scalability, seamless evolutive maintenance…
Autorisation de mise sur le marché françaises de IOPIDINE® 1 % (Apraclonidine) transférée à Essential Pharma en adéquation avec les besoins médicaux et la stratégie d’expansion de l’entreprise
Autorisation de mise sur le marché françaises de IOPIDINE® 1 % (Apraclonidine) transférée à Essential…
Half-year report
DXS INTERNATIONAL PLC (AQSE: DXSP) HALF YEAR RESULTS DXS International plc (“DXS” or the “Company”),…
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial
Pivotal Phase III IMbrave050 study investigating Tecentriq plus Avastin in people with early-stage hepatocellular carcinoma…